A5100459545- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Complement system in diseases
- SARS-CoV-2 and COVID-19 Research
- Protein purification and stability
- Blood groups and transfusion
- Genetics and Neurodevelopmental Disorders
- Adipose Tissue and Metabolism
- Enzyme function and inhibition
- Monoclonal and Polyclonal Antibodies Research
- Advanced biosensing and bioanalysis techniques
- Biosimilars and Bioanalytical Methods
- Muscle Physiology and Disorders
- Hemophilia Treatment and Research
- Mast cells and histamine
- Nutrition and Health in Aging
- Amino Acid Enzymes and Metabolism
Takeda (United States)
2015-2020
Bioanalytica (Switzerland)
2017
The formation of antidrug antibodies (ADA) can interfere with the accurate quantitation therapeutic proteins, leading to significantly underestimated drug concentrations and confounded pharmacokinetic (PK) data interpretation. Although highly desirable, development ADA-tolerant bioanalytical methods enabling unbiased measurement both free ADA-bound presents a considerable challenge. We report herein validation robust LC-MS assay capable quantifying protein immunoglobulin A1 protease (IgAP)...
C1-INH-HAE is caused by activation of plasma kallikrein which subsequently cleaves high-molecular-weight kininogen (HMWK) to generate bradykinin and cHMWK.A novel ion-pair 2D LC-MS/MS assay was developed measure the 46 kDa cHMWK in as a biomarker for C1-INH-HAE. The sample preparation included sodium dodecyl sulfate denaturation, methanol crash, chymotryptic digestion peptide enrichment solid phase extraction.The LLOQ 200 ng/ml. overall recovery combining crash 57.5%. precision method ≤12.7%...
Hereditary angioedema (HAE) is a rare genetic disease caused by deficiency or dysfunction of C1 esterase inhibitor (C1-INH). Plasma C1-INH activity and concentrations complement components 1q 4 (C1q, C4) are critical to the HAE diagnosis. We describe novel multiplexed assay simultaneously measure C1-INH, C1q, C4 levels in dried blood spot (DBS) patients. The proteins were extracted from 3 mm punches DBS samples subsequently digested trypsin. signature peptide derived each protein was...
Develop LC-MS/MS-based assays to measure total and free complement C5 in cynomolgus monkey serum as a target engagement biomarker for pharmacokinetic/pharmacodynamic correlation study. Materials & methods/results: The C5-specific signature peptide derived from pellet digestion of proteins with without prior immunodepletion the drug-bound by protein A beads was quantified assess levels, respectively. Conditions were optimized ensure complete depletion IgGs (and C5). effect sample dilution on...
Aim: Myostatin (MSTN) is an attractive therapeutic target for the treatment of muscle degeneration-related diseases and being evaluated as a engagement biomarker. Methods: A sensitive 2D-LC-MS/MS assay was developed to quantify MSTN in different animal species. Sample preparation involved SDS denaturation serum proteins followed by tryptic digestion peptide enrichment SPE. Results: The validated with LLOQ 2.5 ng/ml rat monkey serum. precision within 13.7%, bias ±12.6% all quality control...